The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of peptides having amino acid similarity with IL13RA2, the said antigenic peptide being selected in the group consisting of sequences described in the specification.

Tolerogenic compositions are disclosed that are of use for inducing a tolerogenic immune response to a CRISPR-Cas effector polypeptide in a subject. In some aspects, the tolerogenic composition includes: a) one or more microparticles; b) one or more regulatory T cell (Treg) stimulating agents encapsulated within each microparticle; and c) a CRISPR-Cas effector polypeptide or immunogenic fragment thereof, or a fusion polypeptide comprising a CRISPR-Cas effector polypeptide or immunogenic fragment thereof. In other aspects, the tolerogenic composition includes a) a dissolvable microneedle array; b) one or more agents that promote differentiation of tolerogenic DCs in the dissolvable microneedle array; and c) a CRISPR-Cas effector polypeptide or immunogenic fragment thereof, or a fusion polypeptide comprising a CRISPR-Cas effector polypeptide or immunogenic fragment thereof.

The invention relates to variants of interleukin-2 (IL2). In one embodiment, the IL2 variants activate effector T cells over regulatory T cells. In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted at at least a position having an acidic or basic amino acid residue in wild type human IL2 that contacts the alpha subunit of the IL2 receptor complex (I12K). Alternatively, the mutein of human IL2 or of a functional variant of human IL2 comprises at least (i) one or more amino acid substitutions which reduce the affinity for the alpha subunit of II_2K and (ii) one or more amino acid substitutions which enhance the affinity for II_2K. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

In certain embodiments, this disclosure relates to conjugates including GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically, the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors including nucleic acid encoding polypeptide conjugates, and protein expression systems including these vectors such as infectious viral particles and host cells including such nucleic acids.

Disclosed herein are compositions and methods for treating solid tumors with yeast-based formulations.

A vaccine is disclosed which comprises a pharmaceutically acceptable carrier and Gramnegative bacteria, genetically modified to express: at least one disease-associated antigen, linked to a signal sequence belonging to a type II secretion system; and the at least one disease-associated antigen linked to a signal sequence belonging to a type III secretion system. Uses thereof are also disclosed.

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).

The invention includes lipid nanoparticles (LNP) capable of eliciting a modulated immune response against an antigen in a subject. The LNPs comprise: (a) at least one first nucleoside-modified ribonucleic acid (RNA) encoding an antigen; (b) at least one second nucleoside-modified RNA encoding a cytokine or immune receptor (such as but not limited to a cytokine receptor); and (c) at least one ionizable lipid. The invention also includes pharmaceutical compositions comprising the LNP of the invention, as well as a method of eliciting a modulated immune response against an antigen in a subject, the method comprising administering an effective amount of a pharmaceutical compositions comprising the LNP of the invention.

Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.

This invention relates engineered extracellular vesicles (EVs) comprising a membrane-bound interleukin-2 (IL-2) molecule and/or functional fragment thereof, a major histocompatibility (MHC) molecule and/or functional fragment thereof, and one or more costimulatory molecule, each expressed on the surface membrane of the EV. The invention further relates to compositions, cells and kits comprising the same, and methods of using and making the same.